Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Macupatide · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Macupatide Dose 1 | EXPERIMENTAL | Participants will receive macupatide subcutaneously (SC) |
| Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 2 + Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Macupatide (Macupatide + Eloralintide Placebo) | EXPERIMENTAL | Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC |
| Eloralintide (Elorlintide + Macupatide Placebo) | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide placebo SC |
| Macupatide + Eloralintide | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide SC |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | PLACEBO_COMPARATOR | Participants will be administered eloralintide placebo SC and macupatide placebo SC |
| Macupatide ＋ placebo | EXPERIMENTAL | Macupatide and placebo administered subcutaneously (SC) |
| Eloralintide + placebo | EXPERIMENTAL | Eloralintide and placebo administered SC |
| Macupatide Dose A + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| Macupatide Dose B + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| Name | Type | Description |
|---|---|---|
| Macupatide | DRUG | Administered SC |
| Eloralintide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Macupatide Placebo | DRUG | Administered SC |
| Eloralintide Placebo | DRUG | Administered SC |
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have ...
Top 20 of 32 competitors
Macupatide is an investigational small molecule being studied for weight management in adults with obesity or overweight. It is also being evaluated in combination with eloralintide in people with obesity or overweight who have type 2 diabetes. Macupatide is not approved and remains in clinical development.
Macupatide is a peptide-based small molecule, classified under the -tide (peptide) target class. Its specific molecular target is not disclosed in available clinical trial information. The drug is being investigated for its effects on weight management in metabolic conditions.
Macupatide is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. Eli Lilly is conducting clinical trials of Macupatide in multiple countries, including the United States, Argentina, Australia, and Japan.
Macupatide is in Phase 2 clinical development. Two Phase 2 trials are currently recruiting participants, and one Phase 1 trial is not yet recruiting. Macupatide is investigational and has not been approved by regulatory authorities.
Macupatide is being studied in two active Phase 2 trials: NCT07215559, which enrolls 200 adults with obesity or overweight and type 2 diabetes, and NCT07589608, which enrolls 400 adults with obesity or overweight. A Phase 1 trial, NCT07765511, is planned in Japan.
Yes, Macupatide is also known as LY3532226. Clinical trial records list Macupatide (LY3532226) as the investigational drug. This alternative name may appear in scientific literature and trial registrations, so both names refer to the same compound.